Tally M Largent-Milnes

List of Publications by Year
in descending order

66 papers	1,634 citations	257450 24 h-index	330143 37 g-index
69 all docs	69 docs citations	69 times ranked	2003 citing authors

#	Article	IF	Citations
1	Regulation of mitochondrial fission by GIPC-mediated Drp1 retrograde transport. Molecular Biology of the Cell, 2022, 33, mbcE21060286.	2.1	10
2	Î²IV-spectrin as a stalk cell-intrinsic regulator of VEGF signaling. Nature Communications, 2022, 13, 1326.	12.8	11
3	Extracellular Alterations in pH and K+ Modify the Murine Brain Endothelial Cell Total and Phospho-Proteome. Pharmaceutics, 2022, 14, 1469.	4.5	1
4	Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression. Cannabis and Cannabinoid Research, 2021, 6, 401-412.	2.9	8
5	An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine. Cephalalgia, 2021, 41, 404-416.	3.9	4
6	The Effects of Repeated Morphine Treatment on the Endogenous Cannabinoid System in the Ventral Tegmental Area. Frontiers in Pharmacology, 2021, 12, 632757.	3.5	8
7	Green Light Antinociceptive and Reversal of Thermal and Mechanical Hypersensitivity Effects Rely on Endogenous Opioid System Stimulation. Journal of Pain, 2021, 22, 1646-1656.	1.4	11
8	Sex hormones regulate NHE1 functional expression and brain endothelial proteome to control paracellular integrity of the blood endothelial barrier. Brain Research, 2021, 1763, 147448.	2.2	4
9	Analgesic Potential of Terpenes Derived fromCannabis sativa. Pharmacological Reviews, 2021, 73, 1269-1297.	16.0	25
10	Sex differences in the expression of the endocannabinoid system within V1M cortex and PAG of Sprague Dawley rats. Biology of Sex Differences, 2021, 12, 60.	4.1	23
11	Brain Penetrant, but not Peripherally Restricted, Synthetic Cannabinoid 1 Receptor Agonists Promote Morphine-Mediated Respiratory Depression. Cannabis and Cannabinoid Research, 2021, , .	2.9	5
12	Glial neuroimmune signaling in opioid reward. Brain Research Bulletin, 2020, 155, 102-111.	3.0	33
13	Heat shock protein 90 inhibitors block the antinociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models. Pain, 2020, 161, 1798-1807.	4.2	8
14	Acute visceral pain relief mediated by A3AR agonists in rats: involvement of N-type voltage-gated calcium channels. Pain, 2020, 161, 2179-2190.	4.2	21
15	Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents. Pain, 2020, 161, 2107-2118.	4.2	19
16	Editorial: Novel Molecular Targets for the Treatment of Pain. Frontiers in Molecular Neuroscience, 2020, 13, 625714.	2.9	0
17	Functional NHE1 expression is critical to blood brain barrier integrity and sumatriptan blood to brain uptake. PLoS ONE, 2020, 15, e0227463.	2.5	8
18	Synthesis and Structureâ€“Activity Relationships of 5â€²-Aryl-14-alkoxypyridomorphinans: Identification of a Î¼ Opioid Receptor Agonist/Î´ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects. Journal of Medicinal Chemistry, 2020, 63, 7663-7694.	6.4	21

#	Article	IF	Citations
19	DAGLÎ± Inhibition as a Non-invasive and Translational Model of Episodic Headache. Frontiers in Pharmacology, 2020, 11, 615028.	3.5	11
20	Chronic Morphine-Induced Changes in Signaling at the A₃Adenosine Receptor Contribute to Morphine-Induced Hyperalgesia, Tolerance, and Withdrawal. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 331-341.	2.5	30
21	Title is missing!. , 2020, 15, e0227463.		0
22	Title is missing!. , 2020, 15, e0227463.		0
23	Title is missing!. , 2020, 15, e0227463.		0
24	Title is missing!. , 2020, 15, e0227463.		0
25	A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 9-25.	2.5	47
26	Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10557-10562.	7.1	76
27	Animal Models for the Study of Bone-Derived Pain. Methods in Molecular Biology, 2019, 1914, 391-407.	0.9	6
28	Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain. Neurobiology of Pain (Cambridge, Mass), 2019, 5, 100022.	2.5	46
29	A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain. Journal of Pain, 2018, 19, 612-625.	1.4	19
30	Continuous remote ischemic conditioning attenuates cognitive and motor deficits from moderate traumatic brain injury. Journal of Trauma and Acute Care Surgery, 2018, 85, 48-53.	2.1	11
31	Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery. ENeuro, 2018, 5, ENEURO.0116-18.2018.	1.9	26
32	Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain. Pain, 2018, 159, 1814-1823.	4.2	29
33	Chronic morphine exposure potentiates p-glycoprotein trafficking from nuclear reservoirs in cortical rat brain microvessels. PLoS ONE, 2018, 13, e0192340.	2.5	15
34	Remote ischemic conditioning preserves cognition and motor coordination in a mouse model of traumatic brain injury. Journal of Trauma and Acute Care Surgery, 2017, 83, 1074-1081.	2.1	19
35	Long-lasting antinociceptive effects of green light in acute and chronic pain in rats. Pain, 2017, 158, 347-360.	4.2	81
36	Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation. Pain, 2017, 158, 1733-1742.	4.2	55

#	Article	IF	Citations
37	Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists. Neuropharmacology, 2017, 116, 59-70.	4.1	70
38	17-Î²-Estradiol induces spreading depression and pain behavior in alert female rats. Oncotarget, 2017, 8, 114109-114122.	1.8	16
39	Effect of Centruroides Antivenom on Reversal of Methamphetamine-Induced Hyperkinesis and Hyperthermia in Rats. Journal of Pharmaceutics & Pharmacology, 2017, 5, 1-5.	0.5	0
40	Structureâ€“Activity Relationships of [des-Arg⁷]Dynorphin A Analogues at the Îº Opioid Receptor. Journal of Medicinal Chemistry, 2016, 59, 10291-10298.	6.4	11
41	The cystine/glutamate antiporter system xc â¯ drives breast tumor cell glutamate release and cancer-induced bone pain. Pain, 2016, 157, 2605-2616.	4.2	32
42	Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain. Pain, 2016, 157, 2709-2721.	4.2	46
43	Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 222-227.	2.2	4
44	Use of Animal Models in Understanding Cancer-induced Bone Pain. Cancer Growth and Metastasis, 2015, 8s1, CGM.S21215.	3.5	39
45	A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain, 2015, 156, 1247-1264.	4.2	71
46	Temperature Differentially Facilitates Spontaneous but Not Evoked Glutamate Release from Cranial Visceral Primary Afferents. PLoS ONE, 2015, 10, e0127764.	2.5	9
47	Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4683-4688.	2.2	10
48	Discovery of Novel Multifunctional Ligands with Î¼/Î´ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain. Journal of Medicinal Chemistry, 2015, 58, 8573-8583.	6.4	16
49	Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands. Bioorganic and Medicinal Chemistry, 2015, 23, 6185-6194.	3.0	2
50	Angiotensinâ€(1â€7) as an Antinociceptive Agent in Cancerâ€Induced Bone Pain. FASEB Journal, 2015, 29, 897.4.	0.5	0
51	External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1. Journal of Neurophysiology, 2014, 112, 2697-2706.	1.8	14
52	Physiological temperatures drive glutamate release onto trigeminal superficial dorsal horn neurons. Journal of Neurophysiology, 2014, 111, 2222-2231.	1.8	12
53	Capsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in rats. Journal of Chemical Neuroanatomy, 2014, 61-62, 1-12.	2.1	23
54	Animal models for opioid addiction drug discovery. Expert Opinion on Drug Discovery, 2014, 9, 1345-1354.	5.0	12

#	Article	IF	Citations
55	Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4975-4978.	2.2	11
56	Disease modification of breast cancerâ€“induced bone remodeling by cannabinoid 2 receptor agonists. Journal of Bone and Mineral Research, 2013, 28, 92-107.	2.8	64
57	Tachykinin NK1 receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation. European Journal of Pharmacology, 2012, 684, 64-70.	3.5	31
58	Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. Journal of Neuroimmunology, 2012, 244, 23-31.	2.3	43
59	Activation of descending pain-facilitatory pathways from the rostral ventromedial medulla by cholecystokinin elicits release of prostaglandin-E2 in the spinal cord. Pain, 2012, 153, 86-94.	4.2	41
60	Discovery of a Potent and Efficacious Peptide Derivative for Î´/Î¼ Opioid Agonist/Neurokinin 1 Antagonist Activity with a 2â€²,6â€²-Dimethyl-<scp>l</scp>-Tyrosine: In vitro, In vivo, and NMR-Based Structural Studies. Journal of Medicinal Chemistry, 2011, 54, 2029-2038.	6.4	30
61	Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain. Brain Research, 2011, 1395, 1-11.	2.2	32
62	Recently patented and promising ORL-1 ligands: where have we been and where are we going?. Expert Opinion on Therapeutic Patents, 2010, 20, 291-305.	5.0	32
63	A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sciences, 2010, 86, 646-653.	4.3	71
64	Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral Î¼-opioid receptors,. European Journal of Pharmacology, 2008, 583, 62-72.	3.5	88
65	Oxycodone Plus Ultra-Low-Dose Naltrexone Attenuates Neuropathic Pain and Associated Î¼-Opioid Receptorâ€“Gs Coupling. Journal of Pain, 2008, 9, 700-713.	1.4	64
66	A Structureâ€“Activity Relationship Study and Combinatorial Synthetic Approach of C-Terminal Modified Bifunctional Peptides That Are Î´/Î¼ Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists. Journal of Medicinal Chemistry, 2008, 51, 1369-1376.	6.4	48